Alcaftadine 0.25% Versus Olopatadine 0.2% In Prevention Of Ocular Itching In Allergic Conjunctivitis

被引：2
|
作者：
McLaurin, Eugene B. [1 ]
Marsico, Nicholas P. [2 ]
Ciolino, Joseph B. [3 ]
Villanueva, Linda [4 ]
Williams, Julia M. [4 ]
Hollander, David A. [4 ]
机构：
[1] Total Eye Care PA, Memphis, TN USA
[2] East West Eye Inst, Los Angeles, CA USA
[3] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Boston, MA USA
[4] Allergan Pharmaceut Inc, Irvine, CA 92715 USA
来源：
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY | 2014年 / 133卷 / 02期
关键词：
D O I：
10.1016/j.jaci.2013.12.986
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
961
引用
收藏
页码：AB278 / AB278
页数：1
相关论文
共 50 条
  • [11] Olopatadine 0.2% is effective for the once daily treatment of the ocular signs and symptoms associated with allergic conjunctivitis
    Abelson, MB
    Gomes, PJ
    Welch, DL
    Pasquine, TA
    Vogelson, C
    Gross, RD
    Turner, FD
    Bergamini, MVW
    Robertson, SM
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2004, 45 : U527 - U527
  • [12] Comparison of effects of alcaftadine and olopatadine on conjunctival epithelium and eosinophil recruitment in a murine model of allergic conjunctivitis
    Ono, Santa J.
    Lane, Keith
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2011, 5 : 77 - 84
  • [13] Observer-masked trial comparing efficacy of topical olopatadine (0.1%), bepotastine (1.5%), and alcaftadine (0.25%) in mild to moderate allergic conjunctivitis
    Dudeja, Lakshey
    Janakiraman, Anuja
    Dudeja, Ishani
    Sane, Kaustubh
    Babu, Manohar
    INDIAN JOURNAL OF OPHTHALMOLOGY, 2019, 67 (09) : 1400 - 1404
  • [14] Olopatadine ophthalmic solution decreases itching and redness associated with allergic conjunctivitis.
    Spitalny, L
    Abelson, M
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 1996, 37 (03) : 2730 - 2730
  • [15] Update and clinical utility of alcaftadine ophthalmic solution 0.25% in the treatment of allergic conjunctivitis
    Chigbu, DeGaulle I.
    Coyne, Alissa M.
    CLINICAL OPHTHALMOLOGY, 2015, 9 : 1215 - 1225
  • [16] Evaluation of the effects of olopatadine ophthalmic solution, 0.2% on the ocular surface of patients with allergic conjunctivitis and dry eye
    Mah, F. S.
    O'Brien, T.
    Kim, T.
    Torkildsen, G.
    CURRENT MEDICAL RESEARCH AND OPINION, 2008, 24 (02) : 441 - 447
  • [17] Clinical Pharmacology of Alcaftadine, a Novel Antihistamine for the Prevention of Allergic Conjunctivitis
    Bohets, Hilde
    McGowan, Claude
    Mannens, Geert
    Schroeder, Nathalie
    Edwards-Swanson, Kimberly
    Shapiro, Aron
    JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS, 2011, 27 (02) : 187 - 195
  • [18] A multicenter evaluation of the efficacy and duration of action of alcaftadine 0.25% and olopatadine 0.2% in the conjunctival allergen challenge model
    Ackerman, Stacey
    D'Ambrosio, Francis, Jr.
    Greiner, Jack V.
    Villanueva, Linda
    Ciolino, Joseph B.
    Hollander, David A.
    JOURNAL OF ASTHMA AND ALLERGY, 2013, 6 : 43 - 52
  • [19] A comparison of olopatadine 0.2% ophthalmic solution versus fluticasone furoate nasal spray for the treatment of allergic conjunctivitis
    Rosenwasser, Lanny J.
    Mahr, Todd
    Abelson, Mark B.
    Gomes, Paul J.
    Kennedy, Kathryn
    ALLERGY AND ASTHMA PROCEEDINGS, 2008, 29 (06) : 644 - 653
  • [20] Olopatadine is effective for the prevention and treatment of the signs and symptoms of allergic conjunctivitis
    Greiner, JV
    Spindel, GP
    Gomes, PJ
    Vogelson, CT
    Amin, D
    Bergamini, MVW
    Robertson, SM
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2003, 44 : U312 - U312
12345